



Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report

Kateřina Ryšánková, Jaromír Gumulec, Michal Grepl, Jan Krhut

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Crocetto F, Italy; Imai Y, Japan

Received: March 30, 2023

Peer-review started: March 30, 2023

First decision: April 26, 2023

Revised: May 16, 2023

Accepted: June 26, 2023

Article in press: June 26, 2023

Published online: August 6, 2023



Kateřina Ryšánková, Michal Grepl, Jan Krhut, Department of Urology, University Hospital Ostrava, Ostrava 70852, Czech Republic

Kateřina Ryšánková, Michal Grepl, Jan Krhut, Department of Surgical Studies, Faculty of Medicine, Ostrava University, Ostrava 70300, Czech Republic

Jaromír Gumulec, Department of Haematology, University Hospital Ostrava, Ostrava 70852, Czech Republic

Jaromír Gumulec, Department of Internal Medicine, Faculty of Medicine, Ostrava University, Ostrava 70300, Czech Republic

Corresponding author: Kateřina Ryšánková, MD, Doctor, Department of Urology, University Hospital Ostrava, Tr. 17. listopadu 1790, Ostrava 70852, Czech Republic.

rysankovak@email.cz

Abstract

BACKGROUND

Acquired haemophilia (AH) is a serious autoimmune haematological disease caused by the production of auto-antibodies against coagulation factor VIII. In some patients, AH is associated with a concomitant malignancy. In case of surgical intervention, AH poses a high risk of life-threatening bleeding.

CASE SUMMARY

A 60-year-old female patient with multiple recurrences of non-muscle invasive bladder cancer underwent transurethral tumour resection. A severe haematuria developed postoperatively warranting two endoscopic revisions; however, no clear source of bleeding was identified in the bladder. Subsequent haematological examination established a diagnosis of AH. Treatment with factor VIII inhibitor bypass activity and immunosuppressive therapy was initiated immediately. The patient responded well to the therapy and was discharged from the hospital 21 d after the primary surgery. At the 38-mo follow-up, both AH and bladder cancer remained in complete remission.

CONCLUSION

AH is a rare, life-threatening haematological disease. AH should be considered in patients with persistent severe haematuria or other bleeding symptoms, especially if combined with isolated activated partial thromboplastin time prolongation.

Key Words: Acquired haemophilia A; Bladder cancer; Bleeding; Complication; Surgery; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Patients with acquired haemophilia A, even those who have never experienced any previous haemorrhagic event, are at high risk of severe life-threatening bleeding in case that they need surgery. It is a rare disease that is often overlooked in the differential diagnosis, resulting in a delay with the risk of life-threatening consequences. Therefore, it is essential to avoid underestimating of the isolated prolongation of the activated partial thromboplastin time or other altered coagulation parameters detected prior to surgery.

Citation: Ryšánková K, Gumulec J, Grepl M, Krhut J. Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report. *World J Clin Cases* 2023; 11(22): 5338-5343

URL: <https://www.wjgnet.com/2307-8960/full/v11/i22/5338.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i22.5338>

INTRODUCTION

Haemophilia is a gonosomal, recessively inherited bleeding disorder. Haemophilia A is caused by a mutation in the gene that encodes coagulation factor VIII, while haemophilia B is caused by a mutation in the gene that encodes coagulation factor IX. The prevalence of haemophilia A is 1/5000 and that of haemophilia B is 1/30000[1]. Haemophilia is diagnosed based on typical clinical symptoms, laboratory evaluation, and genetic tests. In most cases, it is treated by coagulation factor substitution.

Acquired haemophilia (AH) is much less understood. This serious haematological disease is caused by the production of auto-antibodies against coagulation factor VIII. The estimated incidence is 0.2-1.5/1000000, but many cases remain undiagnosed[2,3]. The pathogenesis of AH is unknown. In some patients, AH is associated with a concomitant malignancy or autoimmune disease. The association of AH with bladder cancer is rare[2]. Here, we describe a previously undiagnosed patient with AH, in whom an uncomplicated transurethral resection of non-muscle invasive bladder cancer led to severe haematuria.

CASE PRESENTATION

Chief complaints

A 60-year-old woman developed severe haematuria after elective endoscopic surgery - transurethral resection of multiple recurrent bladder tumours.

History of present illness

In August 2019, a small recurrence developed, and the patient was referred for another transurethral resection of the bladder tumour (TURBT). At the time of hospital admission, the patient had a normal prothrombin time; however, her activated partial thromboplastin time (APPT) was prolonged. This abnormal laboratory finding was initially missed. Immediately after the TURBT, severe haematuria developed. The precipitous drop of haemoglobin to a value of 70 g/L and haemorrhagic shock required intensive care including blood transfusions and coagulation factor substitution. In order to identify the source of bleeding, two consecutive endoscopic revisions were performed within the next 7 d. No clear source of haematuria was identified.

History of past illness

In July 2018, a bladder tumour was diagnosed during an ultrasound examination, and a TURBT was performed. Histology had revealed a non-invasive low-grade urothelial carcinoma. A single dose of intravesical therapy with mitomycin C was administered. At that time, all coagulation parameters were normal, and no postoperative complications developed. In March 2019, multiple superficial recurrences were identified, warranting another TURBT. A histological examination confirmed a non-invasive, low-grade urothelial carcinoma. There were no complications during or after this surgery as well.

Personal and family history

The patient had a history of hypertension and osteoporosis, but no other severe comorbidities. She did not report any previous symptoms of coagulopathy. Her family history regarding bleeding disorders was negative.

Physical examination

The patient's physical examination revealed only haematuria, without other bleeding symptoms.

Laboratory examinations

Changes in the coagulation factors over time are shown in [Table 1](#).

Imaging examinations

Ultrasound examination of the upper urinary tract did not reveal any major pathology.

FINAL DIAGNOSIS

Seven days after the primary surgery, due to persistent haematuria, a haematological examination was performed. At this time point, the haematologist included AH in the differential diagnosis for the first time. Subsequently, at day 10 after the primary TURBT, a final diagnosis of AH was made. Changes in the coagulation factors over time are shown in [Table 1](#).

TREATMENT

Before the final diagnosis was made, two consecutive endoscopic revisions were performed, and the patient received eight units of plasma, four units of erythrocytes without buffy coat, and activated recombinant factor VII (NovoSeven, Novo Nordisk A/S, Denmark) with no effect on bleeding. After confirmation of AH, treatment with factor VIII inhibitor bypass activity and immunosuppressive therapy (prednisone with cyclophosphamide) was immediately initiated, according to current guidelines[4]. In a course of 6 d, the bleeding subsided and haematuria gradually stopped. On day 10 after treatment initiation, normal activity of the factor VIII was confirmed and the level of factor VIII antibodies decreased.

OUTCOME AND FOLLOW-UP

On day 21 after the primary TURBT, the patient was discharged from the hospital. The immunosuppressive therapy dose was gradually reduced, but in February 2020, a relapse of AH was detected based on laboratory results, without bleeding symptoms. Thus, a second line of immunosuppressive treatment was started, with a monoclonal antibody against the CD20 antigen (rituximab). Gradually, the laboratory parameters normalized, and disease remission was achieved. In June 2020, another recurrence of bladder cancer was detected. No specific preventive haematologic measures were adopted prior to surgery, as coagulation parameters were normal at that time. The TURBT and the postoperative course were without complications. Subsequently, the patient received a one-year course of intravesical chemotherapy, as recommended by the European Association of Urology guidelines[5]. As of February 2023, both AH and bladder cancer are in complete remission. The patient attends regular urology and haematology follow-ups. [Figure 1](#) offers the course of disease and therapy of AH.

DISCUSSION

AH is a rare, potentially life-threatening autoimmune disease. In general, the incidence of AH is similar in both sexes. It is higher in women between 20 and 40 years of age, as AH may develop after childbirth[6]. Additionally, the incidence is known to increase in both men and women over 60 years of age.

AH frequently manifests as a subcutaneous haematoma or bleeding into the muscles, gastrointestinal or urogenital tract, epistaxis, or intracranial bleeding. Bleeding into the joints, typical for congenital haemophilia, occurs infrequently in AH[7,8]. Up to 10% of patients with AH remain asymptomatic. AH-related mortality is estimated to be 3%[9]. Even after successful treatment, 12%-18% of patients are at risk of relapse; therefore, all patients require long-term monitoring[4].

The aetiology of AH is unknown. About half the cases are idiopathic, and the other half are associated with various conditions, including malignant tumours (most frequently lung or prostate cancer), autoimmune diseases, drug abuse, or allergy. AH in patients with bladder cancer is extremely rare, with only three cases reported to date[10]. Unlike in our case report, a number of risk factors for AH development were reported in all previously reported cases. These included sepsis or lupus anticoagulant. In our case the only potential risk factor for AH development was bladder cancer[2,3,11] ([Table 2](#)). In this case the only symptom was severe post-TURBT haematuria. In contrast, in all three previously reported cases other bleeding symptoms were present, including subcutaneous and intramuscular hematomas, which led to earlier inclusion of coagulopathy in the differential diagnosis.

The AH diagnosis is based on laboratory tests. It is associated with isolated APTT prolongation and antibodies against factor VIII, which reduce its coagulation activity. Both the prothrombin time and the number of platelets are normal. The mixing plasma test is the initial diagnostic tool, but the Bethesda test is considered confirmatory in making the final diagnosis[4]. Neither the level of antifactor VIII antibodies nor factor VIII activity is directly proportional to bleeding




Figure 1 Timeline. Hb: Haemoglobin; AHA: Acquired hemophilia A; TURBT: Transurethral resection of bladder tumour.

severity, but both may predict disease progression, the treatment response, and overall survival rate[9].

Kreuter *et al*[3] suggested that patients with malignancies that fail AH therapy often have advanced or metastatic disease. They also reported that in 20% of patients, curing malignancy led to the disappearance of anti-factor VIII antibodies. The prompt response to immunosuppressive treatment of AH in our patient could be related to her younger age and favourable stage of the disease[12,13].

Table 1 Coagulation parameters and factor VIII inhibitor values over time in a patient with acquired haemophilia

Parameter (physiological range)	Hospital admission (October 2019)	Acquired haemophilia diagnosed (December 11, 2019)	Treatment start (cyclophosphamide + prednisone)	Clinical and laboratory remission (December 2019)	Laboratory relapse (rituximab, February 2020)	Last TURBT (June 2020)
APTT-R (0.8-1.2)	1.71	2.42	2.38	0.98	1.2	0.81
FVIII (50%-150%)	-	2%	0.8%	81.6%	32%	206%
Inhibitor FVIII (0.0-0.8 BU/L)	-	-	33 BU/L	0.8 BU/L	1.0 BU/L	0.3 BU/L
Haemoglobin (120-160 g/L)	118 g/L	87 g/L	86 g/L	113 g/L	113 g/L	138 g/L
Platelets (150-400) × 10 ⁹ /L	293 × 10 ⁹ /L	291 × 10 ⁹ /L	403 × 10 ⁹ /L	366 × 10 ⁹ /L	340 × 10 ⁹ /L	318 × 10 ⁹ /L
INR	1.0	1.04	0.87	0.88	0.93	0.93
Bleeding symptoms	-	Haematuria	Haematuria	-	-	-

INR: International normalized ratio; TURBT: Transurethral resection of bladder tumour.

Table 2 Comparison of the present case to previously reported cases of acquired haemophilia associated with bladder cancer

Parameter (physiological range)	Case 1[3]	Case 2[2]	Case 3[11]	Presented case
	Bladder cancer. Sepsis. Rectal cancer	Bladder cancer. Sepsis	Bladder cancer. Lung mass. Lupus anticoagulant	Bladder cancer
FVIII (50%-150%)	≤ 1%	1%		2%
Inhibitor FVIII (0.0-0.8 BU/L)	64 BU/L	57 BU/L	250 BU/L	33 BU/L
Bleeding symptoms	Hemothorax. Subcutaneous haematoma	Intramuscular haematoma. Subcutaneous haematoma	Intramuscular haematoma. Subcutaneous haematoma	Haematuria
Therapy	Cyclophosphamide and prednisone	Cyclophosphamide and prednisone. Rituximab	Cyclophosphamide and prednisone. Rituximab	Cyclophosphamide and prednisone. Rituximab

Since AH is considered a sporadic disease, the European Acquired Haemophilia registry was founded[14] to promote the development of internationally accepted diagnostic and treatment guidelines. Treatment of AH consists of haemostatic and immunosuppressive therapy. The treatment in patients with mild form of AH starts with corticosteroids. In cases where the levels of anti-factor VIII antibodies are high, combination with cyclophosphamide or rituximab is recommended. Adverse events of immunosuppressive therapy occur in more than 50% of patients[4]. They may include cardiovascular events such as stroke or myocardial infarction, diabetes mellitus, neutropenia, sepsis, and psychiatric disorders[7]. In addition, the rebound elevation of factor VIII may lead to thromboembolic events.

In clinical practice, early diagnosis is important for successful treatment. However, an appropriate diagnosis and subsequent treatment are often delayed, because patients with AH-related bleeding are mostly encountered by physicians without expertise in haematology. In the present case study, the patient was admitted to the hospital with laboratory signs of AH, and despite APTT values in the pathological range and severe bleeding, the diagnosis was delayed by 10 d. It is therefore important that the urologists and other surgical specialists include this disease in their differential diagnosis when encountering prolonged bleeding. Patients with AH, even those who have never experienced any previous haemorrhagic event, are still at high risk of severe life-threatening bleeding associated with surgery. Therefore, it is essential to avoid underestimation of the isolated prolongation of the APTT or abnormalities in any other coagulation parameters detected prior to surgery[4].

CONCLUSION

AH is a rare, potentially life-threatening haematological disease. It is important to consider AH in the differential diagnosis of patients with haematuria or other bleeding symptoms, when combined with isolated APTT prolongation.

FOOTNOTES

Author contributions: Ryšánková K, Grepl M, and Krhut J contributed to the concept and design of this manuscript; Ryšánková K and Gumulec J were involved in the data acquisition; Ryšánková K, Grepl M, and Krhut J wrote the manuscript; Gumulec J and Krhut J edited the manuscript; and all authors approved the final of manuscript.

Supported by conceptual development of research organization, Ministry of Health, Czech Republic, No. FNOs/2023.

Informed consent statement: The patient gave her consent to publication of this data. All treatments administered were according to respective professional guidelines.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/Licenses/by-nc/4.0/>

Country/Territory of origin: Czech Republic

ORCID number: Kateřina Ryšánková 0000-0002-4995-1945; Jan Krhut 0000-0003-4205-5926.

S-Editor: Wang JJ

L-Editor: Wang TQ

P-Editor: Wang JJ

REFERENCES

- 1 Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. *Haematologica* 2019; **104**: 1702-1709 [PMID: 31399527 DOI: 10.3324/haematol.2019.221093]
- 2 Taza F, Suleman N, Paz R, Haas C. Acquired Hemophilia A and urothelial carcinoma. *J Community Hosp Intern Med Perspect* 2021; **11**: 89-93 [PMID: 33552425 DOI: 10.1080/20009666.2020.1836726]
- 3 Kreuter M, Retzlaff S, Enser-Weis U, Berdel WE, Mesters RM. Acquired haemophilia in a patient with gram-negative urosepsis and bladder cancer. *Haemophilia* 2005; **11**: 181-185 [PMID: 15810923 DOI: 10.1111/j.1365-2516.2005.01066.x]
- 4 Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, Di Minno G, d'Oiron R, Salaj P, Jiménez-Yuste V, Huth-Kühne A, Giangrande P. International recommendations on the diagnosis and treatment of acquired hemophilia A. *Haematologica* 2020; **105**: 1791-1801 [PMID: 32381574 DOI: 10.3324/haematol.2019.230771]
- 5 EAU Guidelines. Non-muscle-invasive Bladder Cancer (TaT1 and CIS). [cited 10 January 2023]. Available from: <https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer>
- 6 Collins PW. Treatment of acquired hemophilia A. *J Thromb Haemost* 2007; **5**: 893-900 [PMID: 17461924 DOI: 10.1111/j.1538-7836.2007.02433.x]
- 7 Janbain M, Leissinger CA, Kruse-Jarres R. Acquired hemophilia A: emerging treatment options. *J Blood Med* 2015; **6**: 143-150 [PMID: 26056504 DOI: 10.2147/JBM.S77332]
- 8 Pai M. Acquired Hemophilia A. *Hematol Oncol Clin North Am* 2021; **35**: 1131-1142 [PMID: 34535289 DOI: 10.1016/j.hoc.2021.07.007]
- 9 Knöbl P. Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A. *Drugs* 2018; **78**: 1861-1872 [PMID: 30542801 DOI: 10.1007/s40265-018-1027-y]
- 10 Napolitano M, Siragusa S, Mancuso S, Kessler CM. Acquired haemophilia in cancer: A systematic and critical literature review. *Haemophilia* 2018; **24**: 43-56 [PMID: 28960809 DOI: 10.1111/hae.13355]
- 11 Onitilo AA, Skorupa A, Lal A, Ronish E, Mercier RJ, Islam R, Lazarchick J. Rituximab in the treatment of acquired factor VIII inhibitors. *Thromb Haemost* 2006; **96**: 84-87 [PMID: 16807656 DOI: 10.1160/TH06-03-0183]
- 12 Ferro M, Chiujdea S, Musi G, Lucarelli G, Del Giudice F, Hurle R, Damiano R, Cantiello F, Mari A, Minervini A, Busetto GM, Carrieri G, Crocetto F, Barone B, Caputo VF, Cormio L, Dittono P, Sciarra A, Terracciano D, Cioffi A, Luzzago S, Piccinelli M, Mistretta FA, Vartolomei MD, de Cobelli O. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. *Clin Genitourin Cancer* 2022; **20**: e166-e172 [PMID: 35033480 DOI: 10.1016/j.clgc.2021.12.005]
- 13 Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. *Urology* 2007; **70**: 65-68 [PMID: 17656210 DOI: 10.1016/j.urology.2007.03.024]
- 14 Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). *J Thromb Haemost* 2012; **10**: 622-631 [PMID: 22321904 DOI: 10.1111/j.1538-7836.2012.04654.x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

